Table 3.

Association of ODC haplotypes with risk for adenoma recurrence, Aspirin/Folate Polyp Prevention Study, 1994–2001

HaplotypeFrequency (%) controls/casesRR (95% CI)PaPb
Block 1c
 TCG47.2/41.61.00 (reference)0.011
 GCA23.1/25.51.14 (1.00–1.30)0.06
 GCG21.0/19.21.02 (0.88–1.17)0.84
 GTG8.5/13.01.33 (1.12–1.57)0.001
 Rare0.2/0.71.41 (0.70–2.81)0.34
Block 2d
 GCCT33.3/37.31.00 (reference)0.012
 GCCC31.0/29.70.91 (0.80–1.05)0.20
 CCCT25.2/21.40.85 (0.73–0.98)0.029
 CCTT7.3/5.80.82 (0.64–1.04)0.11
 GTCC2.7/5.71.27 (1.01–1.61)0.044
 Rare0.4/0.10.55 (0.13–2.32)0.41
Block 3e
 TG66.1/64.31.00 (reference)0.63
 TA23.7/25.31.05 (0.93–1.20)0.41
 CG10.2/10.41.06 (0.89–1.27)0.50
Block 4f
 GAAG46.4/41.91.00 (reference)0.19
 CAAA23.8/28.91.17 (1.02–1.33)0.021
 CGAG21.4/20.11.02 (0.88–1.18)0.81
 CAGA7.3/7.41.06 (0.86–1.31)0.57
 Rare0.9/1.61.27 (0.86–1.31)0.33
  • aPer-haplotype relative risk and Wald test P value adjusted for age and sex.

  • bLikelihood ratio test P values for joint test of all haplotypes in the block.

  • cBlock 1 includes rs13000916, rs11694911, and rs2430419.

  • dBlock 2 includes rs818162, rs1049500, rs28362416, and rs7559979.

  • eBlock 3 includes rs28362380 and rs2302615.

  • fBlock 4 includes rs1728148, rs885815, rs2884211, and rs2357551.